Literature DB >> 35397681

Evaluation of the systemic inflammatory response, endothelial cell dysfunction, and postoperative morbidity in patients, receiving perioperative corticosteroid, developing severe mesenteric traction syndrome - an exploratory study.

August Adelsten Olsen1, Rune Broni Strandby2, Pär Ingemar Johansson3, Henrik Sørensen4, Lars Bo Svendsen2, Michael Patrick Achiam2.   

Abstract

OBJECTIVE: To determine whether a severe mesenteric traction syndrome (MTS) leads to increased surgical stress, endothelial dysfunction, and postoperative morbidity in a cohort in which all patients received a single dose of methylprednisolone.
INTRODUCTION: Preoperatively administered corticosteroids lower the incidence of severe MTS and may also attenuate surgical stress and endothelial damage associated with the development of severe MTS, ultimately lowering the postoperative morbidity.
METHODS: This exploratory study analyzed prospectively collected data from 45 patients all receiving 125 mg methylprednisolone. No control group was included. The severity of MTS was graded intraoperatively, and postoperative morbidity was assessed blinded. Blood samples for plasma prostacyclin (PGI2), IL6 and endothelial damage (Syndecan-1, sVEGRF1 and sThrombomodulin) biomarkers were obtained at predefined time points.
RESULTS: Patients undergoing either open liver surgery (n = 23) or Whipple's procedure (n = 22) were included. No differences were found in postoperative morbidity between patients developing and not developing severe MTS. Surgery led to significantly increased plasma levels of biomarkers indicative of surgical stress and endothelial damage. Further, patients developing severe MTS had increased levels of PGI2 (p = 0.05) and lower systemic vascular resistance (p < 0.05) 15 min into surgery. However, when comparing the biomarkers of surgical stress, endothelial damage no differences between patients with and without severe MTS were identified.
CONCLUSION: This exploratory study found that surgery was associated with a pro-inflammatory response and damage to the endothelium. However, no differences were found between patients developing severe MTS and patients developing moderate/no MTS in biomarkers of surgical stress, endothelial damage, or postoperative morbidity. Corticosteroids may therefore attenuate the endothelial damage in patients developing severe MTS. However, as this was an exploratory study, these findings must be confirmed in future randomized controlled studies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Abdominal surgery; Corticosteroids; Endothelial dysfunction; Flushing; Hemodynamics; Mesenteric traction syndrome; Postoperative morbidity; Surgical stress

Mesh:

Substances:

Year:  2022        PMID: 35397681     DOI: 10.1007/s00423-022-02507-7

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  35 in total

1.  Mesenteric traction syndrome or gut in distress.

Authors:  D V Avgerinos; T C Theoharides
Journal:  Int J Immunopathol Pharmacol       Date:  2005 Apr-Jun       Impact factor: 3.219

2.  Severe Postoperative Complications may be Related to Mesenteric Traction Syndrome during Open Esophagectomy.

Authors:  R Ambrus; L B Svendsen; N H Secher; J P Goetze; K Rünitz; M P Achiam
Journal:  Scand J Surg       Date:  2017-03-01       Impact factor: 2.360

3.  Flurbiprofen axetil provides a prophylactic benefit against mesenteric traction syndrome associated with remifentanil infusion during laparotomy.

Authors:  Yohei Fujimoto; Yuki Nomura; Kumiko Hirakawa; Arisa Hotta; Ai Nakamoto; Noriko Yoshikawa; Naoko Ohira; Shigeki Tatekawa
Journal:  J Anesth       Date:  2012-03-02       Impact factor: 2.078

4.  Laser speckle contrast imaging for quantitative assessment of facial flushing during mesenteric traction syndrome in upper gastrointestinal surgery.

Authors:  Linea L Ring; Rune B Strandby; Amalie Henriksen; Rikard Ambrus; Henrik Sørensen; Jens P Gøtze; Lars B Svendsen; Michael P Achiam
Journal:  J Clin Monit Comput       Date:  2018-11-20       Impact factor: 2.502

Review 5.  [Mesenteric traction syndrome].

Authors:  Paul Suno Krohn; Rikard Ambrus; Morten Zaar; Niels H Secher; Lars Bo Svendsen
Journal:  Ugeskr Laeger       Date:  2014-02-17

6.  Remifentanil increases the incidence of mesenteric traction syndrome: preliminary randomized controlled trial.

Authors:  Yuki Nomura; Yusuke Funai; Yohei Fujimoto; Naoto Hori; Kumiko Hirakawa; Arisa Hotta; Ai Nakamoto; Noriko Yoshikawa; Naoko Ohira; Shigeki Tatekawa
Journal:  J Anesth       Date:  2010-08-07       Impact factor: 2.078

7.  Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1.

Authors:  Michael Bucher; Frieder K Kees; Barbara Messmann; Dirk Lunz; Stephan Rath; Marek Zelenka; Hans J Schlitt; Jonny Hobbhahn
Journal:  Eur J Pharmacol       Date:  2006-03-13       Impact factor: 4.432

8.  Prostacyclin mediation of vasodilation following mesenteric traction.

Authors:  J L Seltzer; M E Goldberg; G E Larijani; D E Ritter; M A Starsnic; G L Stahl; A M Lefer
Journal:  Anesthesiology       Date:  1988-04       Impact factor: 7.892

9.  Development of a severe mesenteric traction syndrome during major abdominal surgery is associated with increased postoperative morbidity: Secondary data analysis on prospective cohorts.

Authors:  August A Olsen; Rune B Strandby; Nikolaj Nerup; Rikard Ambrus; Jens Peter Gøtze; Lars Bo Svendsen; Michael P Achiam
Journal:  Langenbecks Arch Surg       Date:  2019-12-09       Impact factor: 3.445

10.  Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery.

Authors:  Paul S Myles; Rinaldo Bellomo; Tomas Corcoran; Andrew Forbes; Philip Peyton; David Story; Chris Christophi; Kate Leslie; Shay McGuinness; Rachael Parke; Jonathan Serpell; Matthew T V Chan; Thomas Painter; Stuart McCluskey; Gary Minto; Sophie Wallace
Journal:  N Engl J Med       Date:  2018-05-09       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.